Electrochemically activated chemotherapy (EAC) works because it is sourcing the body's own enzymatic mechanism, not machinery, at the chemical modification level (figure 1).

​​

​

​

​

​

​

 

​

Figure 1. Schematic overlap between enzymatic P450 bioactivation and electrochemical activation of (s)ubstrate molecules​. Original Source: Boudreau J. (2012). Electrochemical Generation of Toxicants and their Application as Chemotherapeutics. University of Guelph. Page no: 8.

 

What is bioactivation?

Bioactivation is the naturally occurring metabolic process that makes a molecule more reactive. Bioactivation is used in the body for steroid synthesis; food and drug metabolism; as well as playing a preparatory role in the detoxification of various molecules.

​

EAC uses a chemotherapeutic galvanostat/potentiostat (CGP), like The Joey™ from Innovative Potential™, to activate a prodrug molecule in one of two ways:

1. by removing a chaperone or protective functional group; or,

2. by increasing a molecule's general reactivity.

 

The two (2) main benefits of EAC molecules are:

1. EAC starts with non-toxic precursor compounds and then toxifies (i.e.: activates) them to make them pharmacologically effective; and,

2. ​To create molecules with:

• new mechanisms of action; and,

• lower systemic toxicity; and,

• lower risk hazard profiles in cases of spills; and,

• increased transportation safety; and, 

• increased shelf-life; and, 

• decreased sensitivity to storage conditions.

There are some limitations to EAC but the general rule is that:

• if the precursor molecule can enzymatically bioactivate, then EAC will work when the molecule is activated by a CGP by Innovative Potential™.

​​​​

You can think of EAC as a type of bioactivation, but instead of it occurring with an enzyme, a patented CGP machine from Innovative Potential™ is doing the activation.

​​​